Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity. 2015

Jin Cai, and Ligang Liu, and Kwon Ho Hong, and Peng Wang, and Lushen Li, and Meng Cao, and Chunlong Sun, and Xiaoqing Wu, and Xi Zong, and Junqing Chen, and Min Ji
School of Chemistry and Chemical Engineering, Institute of Pharmaceutical Engineering, Southeast University, 87 Dingjiaqiao, Nanjing, Jiangsu 210096, PR China.

A series of phenoxybutanoic acid derivatives were synthesized and tested for their antagonistic activity on the contraction of the rat thoracic aortic ring induced by endothelin-1. Preliminary screening results showed that 6e and 6g with benzoheterocycles demonstrated significant antagonistic activities when compared to the reference compound BQ123. The results from additional assays for the binding affinity and selectivity for endothelin receptors showed that 6e was a selective ETA antagonist with a nanomolar IC50. Moreover, 6e was effective in relieving hypoxia-induced pulmonary arterial hypertension and right ventricular weight ratio. Therefore, 6e may have potential for further development as a therapeutic agent for the treatment of cardiovascular diseases.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D002087 Butyrates Derivatives of BUTYRIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxypropane structure. Butyrate,n-Butyrate,Butanoic Acids,Butyric Acids,Acids, Butanoic,Acids, Butyric,n Butyrate
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D001013 Aorta, Thoracic The portion of the descending aorta proceeding from the arch of the aorta and extending to the DIAPHRAGM, eventually connecting to the ABDOMINAL AORTA. Aorta, Ascending,Aorta, Descending,Aortic Arch,Aortic Root,Arch of the Aorta,Descending Aorta,Sinotubular Junction,Ascending Aorta,Thoracic Aorta,Aortic Roots,Arch, Aortic,Ascending Aortas,Junction, Sinotubular,Root, Aortic,Sinotubular Junctions
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014661 Vasoconstriction The physiological narrowing of BLOOD VESSELS by contraction of the VASCULAR SMOOTH MUSCLE. Vasoconstrictions
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D017466 Receptors, Endothelin Cell surface proteins that bind ENDOTHELINS with high affinity and trigger intracellular changes which influence the behavior of cells. Endothelin Receptors,Receptors, Endothelium-Derived Vasoconstrictor Factor,Endothelin Receptor,Endothelium Derived Vasoconstrictor Factor Receptors,Receptors, Endothelins,Receptor, Endothelin,Receptors, Endothelium Derived Vasoconstrictor Factor
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Jin Cai, and Ligang Liu, and Kwon Ho Hong, and Peng Wang, and Lushen Li, and Meng Cao, and Chunlong Sun, and Xiaoqing Wu, and Xi Zong, and Junqing Chen, and Min Ji
August 2003, Journal of enzyme inhibition and medicinal chemistry,
Jin Cai, and Ligang Liu, and Kwon Ho Hong, and Peng Wang, and Lushen Li, and Meng Cao, and Chunlong Sun, and Xiaoqing Wu, and Xi Zong, and Junqing Chen, and Min Ji
August 2012, Bioorganic & medicinal chemistry letters,
Jin Cai, and Ligang Liu, and Kwon Ho Hong, and Peng Wang, and Lushen Li, and Meng Cao, and Chunlong Sun, and Xiaoqing Wu, and Xi Zong, and Junqing Chen, and Min Ji
March 2004, Bioorganic & medicinal chemistry letters,
Jin Cai, and Ligang Liu, and Kwon Ho Hong, and Peng Wang, and Lushen Li, and Meng Cao, and Chunlong Sun, and Xiaoqing Wu, and Xi Zong, and Junqing Chen, and Min Ji
January 2011, Bioorganic & medicinal chemistry,
Jin Cai, and Ligang Liu, and Kwon Ho Hong, and Peng Wang, and Lushen Li, and Meng Cao, and Chunlong Sun, and Xiaoqing Wu, and Xi Zong, and Junqing Chen, and Min Ji
July 1998, Journal of medicinal chemistry,
Jin Cai, and Ligang Liu, and Kwon Ho Hong, and Peng Wang, and Lushen Li, and Meng Cao, and Chunlong Sun, and Xiaoqing Wu, and Xi Zong, and Junqing Chen, and Min Ji
December 2001, Bioorganic & medicinal chemistry letters,
Jin Cai, and Ligang Liu, and Kwon Ho Hong, and Peng Wang, and Lushen Li, and Meng Cao, and Chunlong Sun, and Xiaoqing Wu, and Xi Zong, and Junqing Chen, and Min Ji
October 2022, Journal of medicinal chemistry,
Jin Cai, and Ligang Liu, and Kwon Ho Hong, and Peng Wang, and Lushen Li, and Meng Cao, and Chunlong Sun, and Xiaoqing Wu, and Xi Zong, and Junqing Chen, and Min Ji
January 2002, Bioorganic & medicinal chemistry letters,
Jin Cai, and Ligang Liu, and Kwon Ho Hong, and Peng Wang, and Lushen Li, and Meng Cao, and Chunlong Sun, and Xiaoqing Wu, and Xi Zong, and Junqing Chen, and Min Ji
August 2013, Bioorganic & medicinal chemistry letters,
Jin Cai, and Ligang Liu, and Kwon Ho Hong, and Peng Wang, and Lushen Li, and Meng Cao, and Chunlong Sun, and Xiaoqing Wu, and Xi Zong, and Junqing Chen, and Min Ji
November 2021, Journal of medicinal chemistry,
Copied contents to your clipboard!